Pioneering GLP-1 therapies targeting diabetes and obesity, this investment solidifies Axplora's leadership in industrial chromatography and next-generation biologics manufacturing.
- The €50+ million investment will enhance Axplora CDMO’s Mourenx site with state-of-the-art facilities and infrastructure improvements.
- Axplora, with its network of nine industrial sites, is a pioneer in industrial chromatography and this investment positions Mourenx as a leading player in the global peptide purification market.
- The project targets diabetes, obesity and related conditions through pioneering GLP-1 therapies, transforming millions of lives worldwide.
Axplora, a global leader in API small molecule and ADC manufacturing, is proud to announce a landmark €50 million investment in its Mourenx site in Southwest France, securing its position as a key player in the fight against cardiovascular and metabolic diseases. Specializing in large-scale API industrial chemistry and chromatography, this transformative project will enhance Mourenx’s capabilities, positioning it as a center of excellence in the Axplora network for contract manufacturing of APIs and drug substances for FDA-approved biologics.
This investment demonstrates Axplora’s dedication to partnering with leading pharmaceutical companies, fostering innovation, supporting local economic growth, and delivering life-changing therapies to patients worldwide. By upgrading Mourenx’s infrastructure and capabilities, Axplora will solidify its position in peptide purification in a biologics environment and support the development of next-generation therapies, including GLP-1 drugs that target diabetes and obesity—some of society’s most urgent health challenges.
"GLP-1 therapies represent a paradigm shift in medicine, offering targeted therapies for complex diseases with unprecedented efficacy and tolerability,” said Arul Ramadurai, Chief Commercial Officer. “This initiative, built on strong customer partnerships, reinforces Axplora’s role as a trusted partner in manufacturing life-changing, breakthrough medicines."
“This project is testament to our pioneering expertise in industrial chromatography, and working closely with our client, we target having the facility BLA-ready in 15 months. To achieve this our internal teams are working closely with partners in a strong cross-functional project team, well-supported by the local authorities. We are looking forward to a bright future at Mourenx,” stated Dr. Pere Patón-Morales, Chief Operating Officer.
Construction and infrastructure development will begin immediately, with first supplies of GLP-1 therapies expected in 2026. This investment ensures the Mourenx site will remain a key contributor to Axplora’s API network well into the 2030s and beyond.
